These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8102489)

  • 21. Somatostatin analogue treatment of neuroendocrine tumours.
    de Herder WW; van der Lely AJ; Lamberts SW
    Postgrad Med J; 1996 Jul; 72(849):403-8. PubMed ID: 8935599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic applications of somatostatin and its analogue octreotide.
    Harris AG; Kokoris SP
    Eur J Med; 1993 Feb; 2(2):97-105. PubMed ID: 7903061
    [No Abstract]   [Full Text] [Related]  

  • 23. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.
    Pollak M; Gallant K; Poisson R; Harris A
    Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of endothelial proliferation by the somatostatin analogue SOM230.
    Adams RL; Adams IP; Lindow SW; Atkin SL
    Clin Endocrinol (Oxf); 2004 Oct; 61(4):431-6. PubMed ID: 15473874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin and octreotide for variceal bleeding.
    Burroughs AK
    J Hepatol; 1991 Jul; 13(1):1-4. PubMed ID: 1680892
    [No Abstract]   [Full Text] [Related]  

  • 26. Commentary: Somatostatin analogs-How we choose, and why.
    Reidy-Lagunes D; Raj N; Saltz L
    Semin Oncol; 2017 Apr; 44(2):157-158. PubMed ID: 28923214
    [No Abstract]   [Full Text] [Related]  

  • 27. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.
    Martinez-Alonso M; Llecha N; Mayorga ME; Sorolla A; Dolcet X; Sanmartin V; Abal L; Casanova JM; Baradad M; Yeramian A; Egido R; Puig S; Vilella R; Matias-Guiu X; Marti RM
    J Int Med Res; 2009; 37(6):1813-22. PubMed ID: 20146879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatostatin imaging function.
    McCready VR; Hickish TF
    Lancet; 1994 Mar; 343(8898):617. PubMed ID: 7906807
    [No Abstract]   [Full Text] [Related]  

  • 29. Somatostatin receptors and breast cancer.
    Cameron Smith M; Orlando C; Serio M; Maggi M
    J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study.
    Kouroumalis E; Skordilis P; Thermos K; Vasilaki A; Moschandrea J; Manousos ON
    Gut; 1998 Mar; 42(3):442-7. PubMed ID: 9577356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential gastrointestinal uses of somatostain and its synthetic analogue octreotide.
    Grosman I; Simon D
    Am J Gastroenterol; 1990 Sep; 85(9):1061-72. PubMed ID: 1975156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Neuroendocrine carcinoma of the breast. Our experience and a proposal of a therapeutic algorithm for a rare tumor].
    Scaramuzzi G; Murgo RM; Cuttitta A; Ciuffreda L
    G Chir; 2008 May; 29(5):203-6. PubMed ID: 18507954
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery and development of somatostatin agonists.
    Marbach P; Bauer W; Bodmer D; Briner U; Bruns C; Kay A; Lancranjan I; Pless J; Raulf F; Robison R; Sharkey J; Soranno T; Stolz B; Vit P; Weckbecker G
    Pharm Biotechnol; 1998; 11():183-209. PubMed ID: 9760681
    [No Abstract]   [Full Text] [Related]  

  • 34. Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma.
    Lin K; Nguyen BD; Ettinger DS; Chin BB
    Clin Nucl Med; 1999 Jan; 24(1):24-8. PubMed ID: 9890489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
    Bernhardt P; Ahlman H; Nilsson O; Benjegård SA; Forssell-Aronsson E
    Cancer Biother Radiopharm; 2003 Apr; 18(2):249-52. PubMed ID: 12804051
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential indications for somatostatin analogs in Cushing's syndrome.
    Arnaldi G; Polenta B; Cardinaletti M; Boscaro M
    J Endocrinol Invest; 2005; 28(11 Suppl International):106-10. PubMed ID: 16625858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma.
    Fougner SL; Borota OC; Berg JP; Hald JK; Ramm-Pettersen J; Bollerslev J
    Clin Endocrinol (Oxf); 2008 Mar; 68(3):458-65. PubMed ID: 17941904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Imaging of metastases from thyroid carcinomas using 111In-pentetreotide scintigraphy].
    Görges R; Eissner D; Kahaly G; Voges E; Kersjes W; Bockisch A
    Nuklearmedizin; 1995 Aug; 34(4):165-9. PubMed ID: 7675648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Role of somatostatin analogs in the treatment of neuroendocrine tumours].
    Cuccurullo V; Cascini GL; Rambaldi PF; Mansi L
    Minerva Endocrinol; 2001 Sep; 26(3):135-43. PubMed ID: 11753236
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.